What is Prevymis used to treat?

Prevymis (letermovir) is used for the prevention of cytomegalovirus (CMV) infection in patients who have received an allogeneic stem-cell transplant (from a matching donor) and patients who have received a kidney transplant.

Cytomegalovirus is a potentially serious viral infection that is more common in patients who are immune-suppressed, such as AIDS patients, people with cancer, and people receiving organ or bone marrow transplants. Transplant recipients who develop CMV infection after the transplant are at increased risk for transplant failure and death.

Prevymis is a CMV DNA terminase complex inhibitor that works to prevent CMV infection by inhibiting viral replication.

Prevymis is indicated for the:

• prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older and weighing at least 6 kg who are CMV seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
• prophylaxis of CMV disease in adult and pediatric patients 12 years of age and older and weighing at least 40 kg who are kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]).

Prevymis is available in three dosage forms:

• tablets - administered orally with or without food.
• oral pellets - administered orally mixed with soft food or via nasogastric tube or gastric tube.
• injection - administered by intravenous infusion via a peripheral catheter or central venous line at a constant rate over 1 hour.

Common adverse reactions:
- in adult and pediatric HSCT patients include nausea, diarrhea, vomiting, peripheral edema, cough, headache, fatigue, and abdominal pain.
- in adult and pediatric kidney transplant patients include diarrhea.